BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

Amid a changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier a commercial product and a candidate in Phase III testing. The 12-year-old biotech now sees more value...
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market. EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative...
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

EMA’s CHMP has backed autologous cells therapies Tecartus, from Gilead, and Lebmeldy, from Orchard, in its October set of opinions. The agency recommended conditional marketing approval for Tecartus brexucabtagene autoleucel from the Kite Pharma Inc....
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet as it prepares for a series of drug approvals, while taking advantage of...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 10, 2020
Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

...target in the allogeneic pipeline for multiple myeloma. UCARTCS1A is the only candidate directed toward SLAMF7/CS1...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...experienced a fatal treatment-emergent adverse event of cardiac arrest. ” The gene-edited cell therapy targets SLAMF7...
...Orexin 2 receptor P2X3 - Purinergic receptor P2X ligand-gated ion channel 3 SLAMF7 (CS1) - SLAM family member 7 BioCentury...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among four additional...
BioCentury | Mar 11, 2020
Finance

Arkin ramping up investments with $140M fund

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end of 2019. As with...
Items per page:
1 - 10 of 552